AYTU

Aytu Bioscience (AYTU) Stock: Gets a Boost on Delays for Antares Pharma's, Xyosted™
  • Aytu Bioscience (AYTU) Stock: Gets a Boost on Delays for Antares Pharma's, Xyosted™

Aytu Bioscience (AYTU) Stock: Gets a Boost on Delays for Antares Pharma’s, Xyosted™

By |January 23rd, 2018|

For Aytu Bioscience and its leading low-T product, Natesto®, the good news keeps coming. Since the beginning of the year, two of Natesto®’s most advanced clinical stage competitors got handed significant FDA Advisory Committee setbacks, with both Lipocine’s (NASDAQ: LPCN) TLANDO® and privately held Clarus Therapeutics’ Jatenzo®, getting tagged with negative panel reviews and […]

Aytu BioScience Gets A Double Bonus From TLANDO® and Jatenzo® Misses
  • Aytu BioScience Gets A Double Bonus From TLANDO® and Jatenzo® Misses

Aytu BioScience Gets A Double Bonus From TLANDO® and Jatenzo® Misses

By |January 17th, 2018|

Catching emerging biotech stocks at their low’s isn’t necessarily difficult, but it does take a willingness to look at the derivatives that make up the whole when analyzing the opportunity. Those that are following Aytu BioScience (NasdaqCM: AYTU) are well aware of the company’s impressive growth in new prescription rates from Natesto®, the company’s […]

Aytu BioScience (AYTU) Stock: Why 2018 May Be The  Breakthrough Year
  • Aytu BioScience (AYTU) Stock: Why 2018 May Be The  Breakthrough Year

Aytu BioScience (AYTU) Stock: Why 2018 May Be The  Breakthrough Year

By |January 16th, 2018|

As the media tends to focus on the activities played out by Big Pharma, it can be easy for investors to overlook the exciting and often revolutionary developments that are happening at niche pharmaceutical companies. Small pharmaceutical companies can be a lucrative prospect for investors, as the niche markets they target usually allow for […]

Aytu BioScience Pushes Natesto® Sales to New Record High
  • Aytu BioScience Pushes Natesto® Sales to New Record High

Aytu BioScience Pushes Natesto® Sales to New Record High

By |December 6th, 2017|

Aytu BioScience on Tuesday of last week again reported record prescription sales for Natesto®, its FDA-approved nasally administered testosterone replacement therapy. Sales for October reached 827 total prescriptions, representing a 17% increase over September totals. Additionally, new prescriptions, as well as the number of new prescribers, which provides the most current and accurate gauge […]

Aytu Bioscience (AYTU) Stock: With Multiple Catalysts Posted, Share Price Is Ridiculously Low
  • Aytu Bioscience (AYTU) Stock: With Multiple Catalysts Posted, Share Price Is Ridiculously Low

Aytu Bioscience (AYTU) Stock: With Multiple Catalysts Posted, Share Price Is Ridiculously Low

By |November 8th, 2017|

Many people follow the age-old adage to forget half of what you read and most of what you hear. And, no matter what side of that spectrum that you reside on, there can be little dispute that the media will report on stories that best fit their customer demographic. Well, likewise – when it […]

Up 36%, Multiple Catalysts Keep Aytu BioScience (AYTU) Stock Moving Higher
  • Up 36%, Multiple Catalysts Keep Aytu BioScience (AYTU) Stock Moving Higher

Up 36%, Multiple Catalysts Keep Aytu BioScience (AYTU) Stock Moving Higher

By |October 23rd, 2017|

Aytu BioScience is continuing its upward trajectory, adding to its already impressive 36% gain since Monday as the company secures an uplisting to the NASDAQ Capital market and will also be the honorary NASDAQ closing bell ringer this Friday, October 20th.

Beyond the uplist, however, recent company accomplishments make AYTU deserved of the share price […]

With Antares Pharma's (ATRS) Xyosted DOA, Is Aytu BioScience (AYTU) The Beneficiary?
  • With Antares Pharma's (ATRS) Xyosted DOA, Is Aytu BioScience (AYTU) The Beneficiary?

With Antares Pharma’s (ATRS) Xyosted DOA, Is Aytu BioScience (AYTU) The Beneficiary?

By |October 17th, 2017|

For those who doubted the value and need for an alternative testosterone replacement therapy product, investors in Antares Pharma were stunned into certainty as they saw over $210 million in market cap evaporate in front of their eyes. The share price devastation came on the news that the FDA said, of Xyosted, that there […]

Aytu BioScience (AYTU) Stock: MiOXSYS Changing Infertility Technology
  • Aytu BioScience (AYTU) Stock: MiOXSYS Changing Infertility Technology

Aytu BioScience (AYTU) Stock: MiOXSYS Changing Infertility Technology

By |August 24th, 2017|

Aytu BioScience investors are counting on Natesto to lead the way toward profitability. And, while Natesto may indeed deliver AYTU to positive cash-flow status, or even net-profit levels within the next year, not recognizing the next strongest product in the lineup, MiOXSYS, would be like avoiding the obvious…not realizing that MiOXSYS is well deserving […]

Aytu Bioscience (AYTU) Stock: Product Sales Spike Higher
  • Aytu Bioscience (AYTU) Stock: Product Sales Spike Higher

Aytu Bioscience (AYTU) Stock: Product Sales Spike Higher

By |July 26th, 2017|

Time and time again, investors get taught a valuable lesson: invest for the longer term, and gamble for the short term. In fact, statistics show that while focused investing may lead to consistent financial gain, gamblers tend to lose almost 100% of the time using that same long-term mindset. For Aytu Bioscience investors, the […]

AYTU Bioscience (AYTU) Banks $2.2 Million, Will Further Advance Natesto
  • AYTU Bioscience (AYTU) Banks $2.2 Million, Will Further Advance Natesto

AYTU Bioscience (AYTU) Banks $2.2 Million, Will Further Advance Natesto

By |March 1st, 2017|

Aytu Bioscience Inc (OTCMKTS: AYTU)

On Wednesday, Aytu Bioscience announced the successful closing of its warrant tender offer, grossing approximately $2.2 million before customary fee’s and expenses are deducted. Net cash available to AYTU will be approximately $2 million, which is expected to be used for working capital and general corporate purposes.
Strength In AYTU Platform Inspires Confidence
Investors […]